MCB-613 is primarily researched for its potential in cancer therapy due to its ability to modulate steroid receptor coactivators (SRCs). It has shown promise in inhibiting the growth of certain cancer cells by disrupting the function of SRCs, which play a critical role in tumor progression. Additionally, MCB-613 is being explored for its role in metabolic diseases, as it can influence pathways related to energy homeostasis and lipid metabolism. Its application in neurodegenerative diseases is also under investigation, given its potential to regulate cellular stress responses. Ongoing studies aim to further elucidate its therapeutic potential and safety profile for clinical use.